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Abstract
In this review, we examine the current status of Staphylococcus aureus vaccine development and the prospects for future vaccines.
Examination of the clinical trials to date show that murine models have not predicted success in humans for active or passive immunization.
A key factor in the failure to develop a vaccine to prevent S. aureus infections comes from our relatively limited knowledge of human
protective immunity. More recent reports on the elements of the human immune response to staphylococci are analysed. In addition, there
is some controversy concerning the role of antibodies for protecting humans, and these data are reviewed. From a review of the current
state of understanding of staphylococcal immunity, a working model is proposed. Some new work has provided some initial candidate
biomarker(s) to predict outcomes of invasive infections and to predict the efﬁcacy of antibiotic therapy in humans. We conclude by looking
to the future through the perspective of lessons gleaned from the clinical vaccine trials.
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Introduction
Staphylococcus aureus is one of the most frequent causes of
serious infections in humans. It strikes people of all ages, but is
most severe in the young, old and patients with immunode-
ﬁciencies such as neutropenia or human immunodeﬁciency
virus (HIV) infection. Nevertheless, it can also strike people
who are young and healthy with devastating effects [1].
Invasive disease is associated with a 20% and higher mortality
[2–5] due to a combination of antibiotic resistance and
multiple virulence factors (Table 1). Bacterial vaccines have
been highly effective in reducing mortality from Haemophilus
inﬂuenzae, Streptococcus pneumoniae and Neisseria meningiditis
[6,7], but an effective staphylococcal vaccine has not been
made [8,9]. This is not because of a lack of clinical trials (see
Table 2), but to date, no human clinical trial has succeeded.
The question is why do clinical trials fail when the vaccine
candidates have performed well in animal models in general,
and murine sepsis models in particular?
There may be several reasons behind the poor outcomes in
human trials. The most logical conclusion is that the protective
immune response in humans is different from that of most
animals, especially mice, and including non-human primates.
Although there is good understanding of protective immunity
in mice, there is limited understanding of the human immune
response [8–11]. In addition, S. aureus is part of the normal
ﬂora of humans, which suggests that the organism has evolved
to thwart most human immune responses [12–14]. Moreover,
we also know that opsonic antibodies have been the basis for
protection in mice and that the biomarker for efﬁcacy of these
antibodies has been activity in the neutrophil-based in vitro
opsonophagocytic assay. However, while opsonophagocytic
activity has proven to be a predictive biomarker for murine
models of infection, this activity has not translated to
protection of humans because all of the failed clinical trials
used this biomarker [8–11]. Because we have no successful
clinical trials of S. aureus vaccine based upon opsonophagocytic
activity in vitro, we cannot deﬁne whether human serum
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already has sufﬁcient opsonophagocytic activity, nor can we
conﬁrm that increasing the amount of activity will not promote
protection. With this in mind, an alternative hypothetical
model based upon the known immune responses in humans is
shown in Fig. 1. The evidence for this model will be discussed
below and may serve as a starting point for deﬁning the human
immune response in more detail so as to provide a basis for
identifying biomarkers for use in future clinical trials.
An analysis of publications concerning a potential associa-
tion of hypogammaglobulinaemia and increased Staphylococcus
aureus infections is provided (Table 1) by returning to the
original reports. In one recent paper [94], references
to articles on hypogammaglobulinemia were mentioned,
attributing it to an increase in S. aureus infections [85,86],
but the primary reports suggest otherwise. Another two
papers [15,16] were cited in [17], but again, a link between
hypogammaglobulinemia and S. aureus infections was not
established.
Another two papers [15,16] were quoted by Anderson
et al. [17] to support the concept that defects in humoral
TABLE 1. Analysis of publications concerning a potential association of hypogammaglobulinaemia and increased incidence of
Staphylococcus aureus infections
Immune
deﬁciency
in the paper
Higher
incidence of S.
aureus infections Comment
Related to
hypo-
gammaglobulinaemia Reference
Rheumatoid arthritis Yes Rheumatoid factor blocks
effective opsonization [93]
No Lee et al. [85]
Reduced T-cell activity Yes T-cell immunity is associated
with S. aureus infections
No Morrison [86]
Blocked receptors on PMNs Yes Polymorphonuclear cells are
needed for killing S. aureus
No Foster [60]
Reduced immunoglobulin No Reports on S. albus and streptococci Mickenberg
et al. [15]
Reduced immunoglobulin No The number of S. aureus
infections was lower than expected
Trakultivakorn
et al. [16]
TABLE 2. Phase II and III clinical trials of active and passive immunization for Staphylococcus aureus and coagulase negative
staphylococci
Compound Product Phase Study design Results
Passive immunization
Treatment
Aurexis Teﬁbazumab
[87]
Humanized monoclonal
anti-clumping factor A
antibodies
II Randomized, double-blind, placebo-controlled
trial of standard treatment plus either Aurexis or
placebo (n = 63)
No differences in adverse events or rate of
death, relapse, or complications
Altastaph [88] Pooled human anti-capsular
polysaccharide (CP) types 5
and 8 antibodies
II Randomized, double-blind, placebo-controlled
trial of patients standard treatment plus Altastaph
or placebo for S. aureus bacteraemia in adults
(n = 40)
No signiﬁcant mortality difference; shorter
length of stay in Altastaph versus placebo
(9 days versus 14 days; p 0.03)
Aurograb (not
published in
peer-reviewed
journal)
Single-chain antibody variable
fragment against ABC
transporter component GrfA
II Unpublished by sponsor Addition of Aurograb to standard therapy for
life-threatening staphylococcal infections
failed to show efﬁcacy
Prevention
Altastaph [89] II Randomized, double-blind, placebo-controlled
trial of Altastaph or placebo for prevention of
nosocomial S. aureus infections in
very-low-birthweight babies (n = 206)
High levels of antibodies; no difference in rate
of invasive S. aureus infection
Veronate [90] Pooled human IgG to ClfA
(S. aureus) and SdrG
(S. epidermidis)
III Double-blind, placebo-controlled trial of INH-21
versus placebo for prevention of staphylococcal
late-onset sepsis in infants with birthweights 500–
1250 g (n = 1983)
No difference in staphylococcal late-onset
sepsis (5% INH-21 versus 6% placebo;
p 0.34)
Pagimaximab [91] Humanized mouse chimeric
monoclonal antibody against
lipoteichoic acid
II Randomized, double-blind, placebo-controlled
dose-ranging study for prevention of
staphylococcal infection in patients with
birthweight between 700 and 1300 g (n = 88)
Deﬁnite staphylococcal sepsis occurred in 0%
(90 mg/kg), 20% (60 mg/kg), and 13%
(placebo) (p 0.11). Findings not conﬁrmed in
Phase III trial
Active immunization
StaphVax [58] Bivalent vaccine of CP 5 and 8
conjugated individually to
recombinant exoprotein A
III Randomized, double-blind, placebo-controlled
trial of StaphVax in prevention of S. aureus
bacteraemia in haemodialysis dependent adults
(n = 1804)
Efﬁcacy in reduction of S. aureus bacteraemia
at 54 weeks non-signiﬁcant (p 0.23); post
hoc efﬁcacy estimate at 40 weeks: 57%
(p 0.02)
V710 [2] IsdB III Randomized, double-blind, placebo-controlled,
event trial of efﬁcacy of V710 to prevent major
S. aureus infection in adults undergoing median
sternotomy (n = 8031)
Study stopped prematurely by data
monitoring committee. No signiﬁcant
efﬁcacy. Vaccine recipients who developed
S. aureus infection were ﬁve times more
likely to die than control recipients who
developed S. aureus infection (23.0 versus 4.2
per 100 person-years
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immunity resulted in more S. aureus infections. However,
analysis of these two citations with acquired hypogammaglob-
ulinaemia showed that the patient sera were ineffective for
Staphylococcus albus (probably Staphylococcus epidermidis), but
the sera were fully opsonic in two of the three patients for
S. aureus [15]. More importantly, none of the patients were
noted to have S. aureus infections. Instead, patients developed
what were in all likelihood pneumococcal infections, including
recurrent pneumonia, sinusitis and otitis. The second paper
referenced by Anderson et al. was by Trakultivakorn et al.
[16]. This study also failed to fully support the idea that low
levels of gamma globulin were the causative factor for an
increased incidence of S. aureus infections in hypogammaglob-
ulinaemic patients. Only one of the six patients had cul-
ture-conﬁrmed S. aureus; however, the source was listed
simply as being isolated from the ‘ear’, but details of the
collection method were not given; hence, it could have been a
skin contaminant. The paper by Trakultivakorn et al. also
summarized data from some earlier papers about patients with
X-linked agammaglobulinaemia. One of these summarized
papers was by Lederman who found only two patients of 96
patients reported with S. aureus. Another 46 patients are
reviewed in the Trakultivakorn paper with no cases of
S. aureus. Hence, of the total number of patients in the
Trakultivakorn paper, only three S. aureus infections occurred
in 148 children with invasive infections. When one considers
that all of the patients included in the Trakultivakorn paper
were infected, this is a very low incidence of S. aureus
infections for children. Therefore, this paper actually supports
the concept that gamma globulin is not an important factor in
preventing S. aureus infections. In summary, scant evidence
supports the hypothesis that defects in opsonins contribute to
increased numbers of S. aureus infections, as has been
previously noted [8,9]. Finally, an analysis of antibody levels
in humans showed no relationship between incidence of
infection and antibody levels [11].
Are anti-idiotype antibodies competing with natural anti-
bodies [18]? The investigators mixed human and murine
antibodies directed against different types of carbohydrates
found on the S. aureus surface, and these antibodies interfered
with one another for opsonization. This is an interesting
hypothesis, but the studies were performed in mice, and to
date there are no clinical data to support this idea. Another
question has been raised: Do anti-poly-N-acetyl-glucosamine
antibodies interfere with antibodies against capsular antigens,
thereby causing vaccine failure [19]? Again, this is a novel
question and some of the sera tested are from humans
convalescing from bacteraemia, but the data on interference
are in vitro plus mouse model work, making this a long
extrapolation to human disease.
In contrast, humans with defects in neutrophil and
cell-mediated immunity do show increased infections with
S. aureus [20,21]. Patients with Job’s syndrome have a marked
increase in S. aureus infections [22–24]. Patients with defects in
cell-mediated immunity also have a greater incidence of
S. aureus infections. This includes patients receiving predni-
sone, having HIV infection, and defects in T helper type 17
(Th17)/interleukin-17 (IL-17) [25,26]. Interestingly, although
the whole-cell pertussis vaccine protected via antibodies, the
subunit pertussis vaccine protects through Th17/IL-17 [27].
Further support for IL-17 in human infection comes from the
observation that IL-6 auto-antibodies reduce IL-17 and
increase incidence of S. aureus infections [28,29].
Animal model data support the idea that Th17/IL-17 are
involved in S. aureus immunity. Transfer of Th17 cells, but not
antibodies, protects mice from S. aureus infections [30,31].
Iron-regulated surface determinant B (IsdB) protects via Th17
[32], and IL-17A is critical for clumping factor A (ClfA)-in-
duced protection in mice [33]. Moreover, Th17 and IL-17
seem to be particularly important for skin and lung protec-
tion [23,24]. Of note, Th17 and IL-17 also drive antimicrobial
peptide development in skin and mucosal cells [24], which
may add to innate protection from S. aureus invading the skin
and respiratory tree. Staphylococcus aureus antigen activation
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FIG. 1. Abbreviations MΦ, macrophage; PSM, phenol-soluble modu-
lins; IL, interleukin; TGF-b, transforming growth factor-b; Th17, T
helper type 17 cells; mAb, monoclonal antibody; V710, IsdB antigen
used in Merck Vaccine trial; C’, complement; SAE, Staphylococcus
aureus enterotoxin E; RORc(, retinoid-related orphan receptor c;
STAT3, signal transducer and activator of transcription 3; Hla, a-toxin;
TSST-1, toxic shock syndrome toxin -1; Luk, leucocidin; PVL, Panton–
Valentine leucocidin (two component toxin made up of LukS-PV and
LukF-PV); IFN-c, interferon-c.
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of dendritic cells releases IL-23, which drives Th17 activation
[34]. In addition, Toll-like receptor 2 (MyD88/IRAK4) recog-
nizes lipoteichoic acid (LTA) and other lipoproteins and is
required for S. aureus immunity [35,36]. In contrast, circulat-
ing peptidoglycan increases IL-10 and attenuates Th1/Th17
cells [37,38]. Finally, phenol-soluble modulins reduce tumour
necrosis factor (TNF), IL-12 and IL-6, but they increase IL-10
[39].
What does an antibody response to an S. aureus antigen tell
us? It is a marker for an immune response, but does not assure
protection. A recent paper concerning antibody responses to
S. aureus immunization overlooked this concept [40]. A good
example of a robust antibody response failing to provide
protection comes from work on the V710 vaccine (IsdB)
[41,42]; whereas, the protective immune response occurs via
Th17-mediated immunity [32]. Similar results were shown for
other potential vaccine antigens aimed at S. aureus, where the
antibodies produced against ClfA [a ﬁbrin(ogen) binding
protein] [33] and Candida albicans adhesin agglutin-like
sequence 3 protein (Als3p) [30,43] were not protective, but
Th17/IL-17 responses proved to be protective. It should be
noted that some protection by antibodies did occur in the liver
when V710 Fc(–) monoclonal antibodies were given to mice.
These monoclonal antibodies stimulated interferon-c, which
activates phagocytes for C’-mediated uptake/killing in murine
models [44]. Of interest, a-haemolysin (Hla) has been found to
induce a Th17 response that contributes to lung damage in
S. aureus pneumonia and that type I interferon provides an
innate protective response by mitigating host cellular ATP loss
[45]. Hence, neutralizing Hla with antibody reduces the direct
damage to host from Hla and reduces the pro-inﬂammatory
effects of Hla.
Although we lack data for antibodies being determinative
in preventing S. aureus infections, there are data suggesting
that anti-toxin antibodies may reduce disease severity.
Patients with antibodies against toxic shock toxin are less
likely to develop toxic shock syndrome, but this has not been
commercially developed because the small number of cases
limits the market [46]. Some clinical trials are underway
employing anti-recombinant Hla and anti-recombinant
LukS-PV (NCT01011335). These trials are supported by the
following animal model data: AT62-IgG (rabbit anti-HLA IgG)
protected mice from pneumonia and intraperitoneal chal-
lenges [47]. A fusion of Hla and Clostridium perfringens a-toxin
(r-aCS) protected red blood cells from lysis [48]. Anti-Hla
antibodies reduce recurrent skin infections in children, but
natural infection does not provoke durable immunity [49].
Similarly, anti-Hla antibodies protect rabbit and Jurkat T cells
from lysis, as does the ADAM10 (the mammalian receptor
for Hla) inhibitor, R66 [50]. Although antibodies to Hla and
Panton–Valentine leukocidin (PVL) are short-lived, anti-Hla
antibody levels did correlate with protection against subse-
quent S. aureus infections in children [49]. Of note, cutaneous
infections do not provide protective levels of antibody to Hla
and PVL to prevent recurrences or invasive infection [49].
Leucotoxin ED binds CCR5 receptor on myeloid cells and T
lymphocytes. The HIV drug, maraviroc (CCR5 inhibitor),
protects mice from S. aureus challenge and from Leucocidin
ED [51]. Finally, other potential toxoids may be suitable for
vaccine based upon the observations that low anti-exotoxin
antibody levels correlate with more severe sepsis when
patients are infected with enterotoxin-producing S. aureus
strains [52], and higher anti-PVL antibody levels correlate with
less severe pneumonia [53]. That enterotoxoids might need to
be given as vaccines is suggested by the fact that S. aureus
bacteraemia in intravenous drug users failed to produce
antibodies against enterotoxin superantigens [www.clinicaltri-
als.gov, NCT00548002], whereas non-enterotoxin superanti-
gens were common and increased following S. aureus
bacteraemia [54]. Hence, there are both human and animal
data suggesting that anti-staphylococcal toxin antibodies may
have efﬁcacy in reducing disease severity.
Insights from Recent Clinical Studies of the
Immune Response to Staphylococcus aureus
In addition to the human clinical data on anti-toxin antibodies
(above), several reports from clinical trials have revealed
information about other aspects of the human immunity to
S. aureus. Recently, Rose et al. [55,56] provided seminal papers
on the human immune response during S. aureus bacteraemia,
which conﬁrm and extend our limited knowledge about the
human immune response. Speciﬁcally, high IL-10 predicts high
mortality; low IL-1b correlates with prolonged bacteraemia.
Previous studies had also suggested that a high IL-10/TNF-a
ratio predicted higher mortality in febrile patients [57]. Of
interest, circulating peptidoglycan increases IL-10 and attenu-
ates Th1/Th17 cells, which may contribute to the mortality
seen in high-level bacteraemia [37,38]. Taken together, these
data suggest that IL-10, TNF-a and IL-1b levels may serve as
biomarkers for disease severity, which could also serve as
biomarkers for vaccine efﬁcacy.
A Working Model of Immunity to
Staphylococcus aureus
Based upon the information provided above, a working model
of S. aureus immunity can be developed (see Fig. 1). Whenever
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possible, it is based upon information known about human
immunology and human responses to S. aureus infections.
Th17 is placed at the centre of the model because this
organizes much of the current data. Activation of Th17 cells
results in enhanced neutrophil activity as well as increased
antimicrobial peptide activity on the mucosal and skin barriers.
This scheme brings together the known increased incidence of
S. aureus infections in patients with neutrophil and cell-med-
iated immune defects. The model also recognizes the role of
IL-6 in activating Th17 cells and IL-10 in decreasing Th17 cell
activity. Moreover, the immunomodulating effects of staphy-
lococcal lipoproteins and phenol-soluble modulins can be seen
as stimulating the release of IL-10, which reduces Th17 cell
activation. Moreover, the clinical ﬁndings that IL-6 autoanti-
bodies increase the incidence of S. aureus infections may also
be seen to reduce Th17 cell activation. Toxins such as
S. aureus enterotoxin can activate ab T cells, which then cause
cd T cells to release IL-6. Finally, a role for antibody
neutralization of toxins, such as toxic shock syndrome toxin-1,
Hla, PVL and leucocidin ED, is shown as distinct activity that is
outside an opsonin role [52]. The fact that antibodies to IsdB
did protect mice is also shown in a separate box because it
protected via activation of interferon-c to enhance clearance
of organisms, but it is not known if such a mechanism is active
in humans.
Conclusions Gleaned from Clinical Vaccine
Trails
Both active and passive immunization have been attempted.
For passive immunization, antibodies against SdrG, ClfA, LTA,
types 5 and 8 capsules, and GrfA have been tested. Active
immunization against IsdB, staphylococcal enterotoxin B, ClfA,
types 5 and 8 capsules, LTA and GrfA have been examined. All
of the trials that have completed phases I and II have been
based upon increasing opsonic antibody to surface antigens.
There is a suspended phase I trial based upon anti-staphylo-
coccal enterotoxin B trial from Bio-Therapeutics
(NCT00974935) and the phase I immunogenicity trial by
GlaxoSmithKline that includes PVL. There are some ongoing
clinical trials using the following antigens: rAls3p-N, fLukS-PV/
rAT, Eap, GST-Can, His-Clf, SdrD, SdrE, IsdA, IsdB, and FhuD2.
Most of the newer attempts are using multiple antigens.
As shown in Table 2, all of the completed phase II and
phase III trials with both passive immunization and active
immunization to date have failed to meet the pre-trial
endpoints. With passive immunization, two strategies have
been attempted: treatment of active staphylococcal infections
as an adjunct in addition to standard treatment; and
prevention of staphylococcal infections in at-risk patient
populations. In the setting of active S. aureus infection, three
compounds have been evaluated. A phase II trial to evaluate a
monoclonal antibody against ClfA (teﬁbazumab/Aurexis; In-
hibitex) for use as an adjunct to standard therapy for patients
with S. aureus bacteraemia failed to demonstrate any signiﬁ-
cant differences in a Composite Clinical Endpoint of death,
relapse, or development of an S. aureus-related complication
not present at baseline. Hypersensitivity reactions developed
in one in 30 patients. A phase II trial of a polyclonal
immunoglobulin of anti-type 5 and anti-type 8 antibodies
(Altastaph; Nabi) also failed to show a signiﬁcant difference in
clinical outcomes among patients with complicated S. aureus
bacteraemia. Interestingly, length of stay among the Altastaph
recipients was signiﬁcantly shorter than placebo (9 days
versus 14 days; p 0.03). Unfortunately, the sponsor has failed
to publish the results of the trial involving Aurograb in a
peer-reviewed format. Three compounds employing passive
immunization have also been evaluated, all in neonates, for
prevention of staphylococcal infections (both S. aureus and
S. epidermidis). Although pagimaximab (Biosynexus), human-
ized mouse chimeric monoclonal antibody against LTA,
exhibited a promising trend in Phase II, these results were
not substantiated in the registration trial that followed.
Two registration trials have evaluated vaccine candidates in
active immunization strategies. Both trials have involved adult
populations with high rates of S. aureus infection. Although this
strategy afforded important advantages in terms of sample size
reduction because of the relatively high event rate of S. aureus
infection, each patient population carried signiﬁcant unavoid-
able complications for trial design related to their co-morbid
conditions, such as high rates of adverse events, relative
immunocompromised state, etc. Nabi conducted a phase III
registrational trial of Staphvax, a bivalent vaccine of capsular
proteins 5 and 8, in 1804 haemodialysis patients with a primary
ﬁstula or synthetic graft vascular access. At the pre-speciﬁed
endpoint of 54 weeks following vaccination, the study failed to
demonstrate protective efﬁcacy in reduced rates of S. aureus
bacteraemia. In post hoc analyses, vaccination exhibited a
statistically signiﬁcant protective effect against S. aureus bac-
teraemia as long as 40 weeks after vaccination (efﬁcacy 57%;
p 0.02) [58]. Based upon this ﬁnding, Nabi conducted a second
registrational trial, again in haemodialysis patients, in which the
sample size was approximately doubled and the primary
endpoint was moved to 6 months after vaccination (versus
54 weeks with the Shineﬁeld study [58]). Inexplicably, this
second StaphVax trial (never published in peer-reviewed
literature) also failed to show efﬁcacy. Merck tested V710, a
vaccine targeting IsdB, in patients undergoing median sternot-
omy. The trial employed an event-driven design. After
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 5), 66–75
70 Clinical Microbiology and Infection, Volume 20 Supplement 5, May 2014 CMI
enrolment of ~ 8000 patients, the Data Monitoring Commit-
tee ﬁrst held, then terminated, the trial based upon failure to
demonstrate efﬁcacy and a higher rate of multiorgan system
failure-related deaths in the V710 recipients. Post hoc analysis
revealed that vaccine recipients who developed S. aureus
infection were ﬁve times more likely to die than control
recipients who developed S. aureus infection (23.0 versus 4.2
per 100 person-years.
What have we learned? First, protection demonstrated in
animal models, especially murine models has not translated
into protection of humans. Second, staphylococcal anti-toxins
have not been studied, yet anti-toxin approaches have
worked very well in other Gram-positive infections. Third,
the use of multiple antigens has not been studied, but this
may well be necessary given the very large number of
virulence factors expressed by S. aureus. Fourth, prevention
of S. aureus infection is a very high standard that may not be
achievable in an organism that is part of the normal ﬂora and
that has learned to evade so many of the human host’s
defences. Aiming at reduced severity, and decreased cost/
length of stay may be more achievable endpoints, although at
least one pilot study to determine the effect of StaphVax on
reduction of nasal carriage demonstrated no effect [59]. Fifth,
V710 showed excess numbers of MRSA in vaccinated patients
[2]. Some MRSA20CCmec type strains are more virulent
[61–65]. However, whereas the mechanisms for this associ-
ation are unknown, one could speculate that this may have
played a role in the larger number of vaccinated patients
showing multi-organ failure. In the end, the discovery that
V710 recipients who developed S. aureus infections were ﬁve
times more likely to die than controls that developed
S. aureus infection suggests the potential for harm due to
an ‘immune-priming’ type process. Although purely specula-
tive, future studies will need to explicitly demonstrate the
absence of such effects in pre-clinical and early clinical
studies.
Future for a Staphylococcus aureus Vaccine
We should not give up hope of developing a staphylococcal
vaccine. Carriers have more infections, but the infections are
less severe [10,11], which strongly suggests that some form of
immunity has developed during prolonged colonization. This
provides another approach to vaccine development, speciﬁ-
cally aimed at reducing the severity of infections rather than
prevention. All of the trials have aimed at prevention of
infection, which is a very high standard for an organism that has
evolved over millennia to survive with the human host.
Possible directions for future research follow.
Anti-toxoid vaccines have not been fully explored. Neu-
tralizing antibodies have been shown to be important in
protection against toxic shock syndrome [46], and there are
data suggesting that anti-Hla may reduce disease severity
[49,50] and inhibitors of the Hla receptor are also protective
[50]. Data surrounding anti- PVL toxins are more controver-
sial, but they may have a role in preventing severe lung damage
in post-inﬂuenza pneumonia [53]. Finally, naturally occurring
antibodies against toxic shock syndrome toxin are recognized
to prevent toxic shock syndrome [66]. Other superantigens,
e.g. enterotoxins, have also been recently evaluated as vaccine
candidates [46]. Hence, the addition of anti-toxin neutralizing
antibodies may prove valuable in a human vaccine to reduce
disease severity, even though opsonic antibodies have not
succeeded.
This brings us to another concept, i.e. multiple vaccines.
Currently, multiple vaccines are being developed for
Escherichia coli, which is another pathogen that is part of the
normal ﬂora: Anti-ﬁmbrial vaccines to prevent urinary tract
infections or anti-Shiga toxoid to prevent haemolytic uraemic
syndrome or anti-adhesive antibodies for childhood diarrhoea
[67–69]. Hence, another vaccine approach for S. aureus
infections would be to design vaccines targeted to prevent
foreign body infections, subcutaneous abscesses, endocarditis
and haemodialysis infections, intensive-care unit pneumonia,
etc. Naturally, more limited spectrum vaccines would be more
costly.
Although anti-toxin antibodies appear to be good biomar-
kers for toxin-mediated S. aureus disease, the difﬁcult ques-
tions arise because we still do not have a biomarker that
predicts protection in humans. We do not know whether a
particular surface antigen will provide protection in humans
because of the lack of a biomarker. Of course, the lack of a
biomarker(s) that predicts efﬁcacy stems directly from our
limited knowledge of the protective immune response in
humans [8,9].
Numerous investigators have suggested that a multiple-anti-
gen vaccine would be more effective [17,70–73], but a lack of
biomarkers deﬁning human protective immunity keep these
proposals in the logical, but strictly hypothetical arena.
There are some data to suggest that improving non-anti-
body responses may be the key to a new and effective
vaccine. Some data suggest that the Th17 immune response is
important. Hence, will Th17 adjuvants help? The duration of
Th17 immunity in humans is unknown, but it is short in mice
[74]. Can the Th17 response be prolonged/enhanced by
unique adjuvants that stimulate CD27/TRAFS? Phytol-based
terpenoids, phytanol (PHIS-01) and phytanuyl Cl (PCl), have
been shown to improve Th17/IL-17 responses [28,74,75].
Th17 immunity has been implicated in mucosal immunity
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against Clostridium difﬁcile [76]; hence, one might speculate
that it also might be valuable in decreasing mucosal coloni-
zation, which might prevent vaginal colonization and toxic
shock syndrome or reduce nasal carriage [92]. Care must be
exercised in developing a robust Th17 response because this
arm of the immune system has been implicated in autoim-
mune diseases [77] and Th17 was induced by the IsdB (V710)
vaccine [32], which was associated with an increase in
multi-organ failure during S. aureus infections [2].
Other novel approaches include using a mutated protein A
immunoglobulin-binding domains as immunogen, which
reduced virulence, improved the immunogenicity of other
antigens, and enhanced opsonophagocytic activity in a murine
model [78]. We know from the elegant work from the van
Strijp laboratory that S. aureus produces a vast array of
products that cripple the host immune system [13,14,79].
Hence, a possible approach that would complement many of
the previous vaccine approaches would be to target SCINs
(staphylococcal complement inhibitors), CHIPS (chemotaxis
inhibitory protein of staphylococci), SSLs (staphylococcal
superantigen-like proteins), etc. to potentiate polymorphonu-
clear cell activity [79,80].
In the ﬁnal analysis, work on the human immune response
and biomarkers has come from Rose’s laboratory [55,56].
Initial low levels of IL-1b [55,56] and high levels of TNF-a [81]
were found in patients with S. aureus prolonged bacteraemia
(>4 days) as compared with those that rapidly cleared their
organisms. Of note, when the isolates from patients with
prolonged bacteraemia were tested in a whole blood killing
assay, lower levels of IL-1b were produced in vitro when
compared with rapidly cleared isolates [81]. In addition,
elevated levels of the anti-inﬂammatory cytokine, IL-10, were
found in patients with higher levels of bacteraemia and higher
mortality [55,56]. These ﬁndings are similar to those reported
for febrile patients wherein high IL-10 and low TNF-a
correlated with increased mortality with multiple species of
organisms [57]. Hence, these biomarkers predict mortality and
clearance of bacteraemia, and reﬂect the virulence of the
particular isolate.
The importance of these seminal studies by Rose’s group
should not be underestimated as they are predictive of outcome
in human S. aureus bacteraemia, and they are mimicked by
cytokine responses in human neutrophils, thereby allowing in
vitro study of future antigens. It should also be noted that these
biomarkers also responded to successful antibiotic therapy,
which also attests to their value, including their use in clinical
trials where both vaccination and antibiotic therapy will
inevitably be used together. These observations are included
in the hypothetical model, which should provide testable
hypotheses for conﬁrming these biomarkers in clinical trials.
Clearly, being able to factor in both the effectiveness of
antimicrobial therapy and the virulence of the strain by using
selected biomarkers will help to dissect out these host and
organism variables from vaccine efﬁcacy.
Finally, during our quest for an S. aureus vaccine, we should
not overlook the immediately available solution of decoloni-
zation to prevent nosocomial S. aureus infections
[59,83,84,95] in addition to excellent infection control prac-
tices. Mupirocin has been used, but resistance for disease
reduction in surgical patients, but resistance is becoming a
problem. Currently, a novel agent, XF-73 that is extremely
rapidly bactericidal is in phase II clinical trials for nasal
decolonization (sponsored by NIH and NIAID) [Clinical
Trials.gov NCT01592214].
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